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survival (PFS) and overall survival (OS). There were 
significant reductions in parameters that describe relative 
levels of choline to NAA and creatine, indicating that the 
treatment caused a decrease in tumor cellularity. Changes 
in the levels of lactate and lipid relative to the NAA from 
contralateral brain were consistent with vascular normal-
ization. Metabolic parameters from the first serial follow-
up scan were associated with PFS and OS, when account-
ing for age and extent of resection. Integrating metabolic 
parameters into the assessment of patients with newly 
diagnosed GBM receiving therapies that include anti-
angiogenic agents may be helpful for tracking changes in 
tumor burden, resolving ambiguities in anatomic images 
caused by non-specific treatment effects and for predict-
ing outcome.
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Introduction
The current standard of care for patients with newly diag-
nosed glioblastoma (GBM) is maximal safe resection, fol-
lowed by radiation therapy and temozolomide [1]. A variety 
of investigational agents are being considered in conjunction 
with this trategy in order to improve outcome. Evaluation 
of combination therapies is complicated by differences in 
their mechanisms of action that lead to difficulties in assess-
ing the spatial extent of tumor and ambiguities in the inter-
pretation of conventional anatomic images. One such effect 
that has been reported to occur in up to 30 % of patients
treated with radiation and temozolomide is pseudoprogres-
sion, which is characterized by an increase in the size of 
Abstract Interpretation of changes in the T1- and 
T2-weighted MR images from patients w th newly diag-
nosed glioblastoma (GBM) treated with standard f c re
in conjunction with anti-angiogenic agents is complicated 
by pseudoprogression and pseudorespon e. The hypoth-
esis being tested in this study was that 3D H-1 magn tic 
resonance spectroscopic imaging (MRSI) provides esti-
mates of levels of choline, creatine, N-acetylaspartate 
(NAA), lactate and lipid that change in response to treat-
ment and that metrics describing these characteristics are 
associated with survival. Thirty-one patients with newly 
diagnosed GBM and being tre ted with r dia ion ther-
apy (RT), temozolomide, erlotinib and bevacizumab were 
recruited to receive serial MR scans tha  included 3-D 
lactate edited MRSI at baseline, mid-RT, post-RT and at 
specific follow-up time points. The data were processed 
to provide estimates of metrics representin  changes in 
metabolite levels relative to normal appear ng brain. Cox 
proportional hazards analysis was appl ed to examine the 
relationship of these parameters with progression free 
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study. External beam radiation therapy (RT) was initiated 
within 5 weeks of diagnosis and delivered an average dose 
of 60 Gy to the tumor site in 2-Gy fractions over a 6-week 
period. Temozolomide was given concurrently and after 
RT at a daily dose of 75 mg/m2. Patients who were not on 
anti-epileptic drugs received 150 mg/day of erlotinib and 
patients who were on anti-epileptic drugs received 500 mg/
day starting on day 1 of RT. Bevacizumab was prescribed 
at a dose of 10 mg/kg IV every 14 days starting in week 2 
of RT. All patients participating in the study gave informed 
consent, according to the guidelines of our institutional 
review board. Overall survival (OS) was calculated as the 
time to death from the start of treatment and progression 
free survival (PFS) as the time from the start of treatment 
to the examination at which the patient was determined to 
have progressed based upon the RANO criteria or the time 
of death if there had been no prior progression [8].
Imaging protocol
Patients received MR exams at multiple time points, includ-
ing following surgical resection but prior to RT (pre-RT), 
between 3 and 5 weeks into treatment (mid-RT), within 2 
weeks after completion of RT (post-RT), and at the next fol-
low-up scan that was approximately 4 months after the base-
line time point (Fup1). All scans were obtained with a 3 T MR 
scanner (GE Healthcare, Milwaukee, WI), the body coil for 
transmission and an 8-channel phased array coil for reception. 
Standard anatomical imaging comprised axial T2-weighted 
fluid attenuated inversion recovery (FLAIR) images (TR/
TE/TI = 9500/122/2375 ms, matrix = 256 × 256, slice thick-
ness = 3 mm, FOV = 24 × 24 cm), and pre- and post-contrast 
volumetric T1-weighted inversion recovery spoiled gradient 
echo images (TR/TE = 8.86/2.50 ms, matrix = 256 × 256, 
slice thickness = 1.5 mm, FOV = 24 × 24 cm, TI = 400 ms,
Flip angle = 15°).
Lactate edited 3D H-1 MRSI data [14] were obtained 
with CHESS water suppression, very selective satura-
tion (VSS) outer volume suppression and PRESS volume 
selection (TR = 1104 or 1300 ms, TE = 144 ms, acquisi-
tion matrix of 16 × 16 ×16 r 8 × 18 × 16, nominal spatial 
resolution of 1 cm3). Phase encoding was applied in the 
right-left and anterior-posterior directions with fly-back tra-
jectories in the superior-inferior direction. An over-PRESS 
factor of 1.5 was applied with VSS bands to avoid chemical 
shift artifacts and to suppress residual lipid signals. The total 
acquisition time was 9.5 min, with 712 complex spectral 
points read indirectly using the EPI train of gradient pulses 
and spectral bandwidth of 988 Hz. The PRESS selected vol-
ume was defined using the anatomic images and generally 
covered the lesion and 200–500 cc of normal tissue. Areas 
with sharply varying magnetic susceptibility and lipid con-
tamination were avoided whenever possible.
the enhancing lesion that ubsequently disappears withou  
further intervention [2].
Given that GBM are characterized by abnormal vas-
culature, there has been gr at interest in using treatment 
regimens that include anti-angiogen c agen s [3–5]. The 
dramatic reduction in the size of the contrast enhancing 
(CE) lesion that was observed following treatme t of r cur-
rent GBM with bevacizumab was very encouraging and led 
to conditional approval for its u . Subsequent studies in 
populations of patients with new y diagnosed GBM have 
shown longer progression free survival but have not estab-
lished a significant improvement in overall survival [6, 7]. 
For cases where the treatment regim  includes such n i-
angiogenic agents, it is not clear whether early reductions 
in the CE lesion are indicative of successful treatment or if 
they are associated with pseudo- or true response.
The ambiguities in interpreting changes in the size of the 
CE lesion have highlighted the need to develop alternative 
approaches for assessing tre tment response. The RANO 
criteria are a first step in that direction [8 ], as they consider 
changes in the cross sectional diameter of both the CE and 
T2 lesion. A further suggestion has been that estimating the 
three dimensional (3D) volumes of the atomic would pro-
vide a more precise assessment of th ir absolute and relative 
changes with time. While providing more precise quantifi-
cation of lesion size is definitely of interest, it is not clear 
whether this would be able to address pseudoprogression and 
pseudoresponse. Having an imaging modality that makes it 
possible to track biological response to therapy is likely to 
be a more promising approach. Previous studies that applied 
H-1 MR spectroscopic imaging (MRSI) to evaluate patients 
with GBM have shown that the magnitude and spatial exte t
of regions with abnormal metabolism is often quite different 
from areas corresponding to the CE nd T  lesions [9–12]. 
This suggests that metabolic imaging can provide comple-
mentary information about changes in tumor burden that 
would be helpful in assessing r sponse to therapy.
The purpose of this study was to obt in 3D H-1 MRSI 
data from a cohort of patients with n wly diagnosed GBM 
being treated with radiation therapy, temozolomide, erlo-
tinib and bevacizumab in order to evaluate treatment 
induced changes in the metabolic characteristics of the 
lesion. The hypothesis being ested was that levels of cho-
line, creatine, N-acetylaspartate (NAA), lactate and lipid 
change in response to treatment and that metrics describing 
these characteristics are associ ted wi h survival.
Methods
Thirty-one patients with pathologically confirmed newly 
diagnosed GBM, who were being treated as part of a single 
institution Phase II clinical trial [13] were recruited for this 
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developed to describe the deviation of choline and NAA in 
regions with normal metabolite levels in the same individ-
ual [19, 20]. The calculation is performed using an auto-
mated, iterative procedure that uses choline and NAA levels 
in the spectral array from each examination separately and 
is independent of the anatomic images. Once the CNI map 
had been generated for each patient and time point, their 
metabolic lesion was defined as the region having values 
greater than or equal to 2 (CNI2). Figure 1 shows an exam-
ple of the spectral data and CNI overlays from the Fup1 
scan for a patient with a relatively large metabolic lesion 
at this time point. The CNI intensities were interpolated to 
the resolution of the anatomic images for display purposes 
and the overlay was thresholded to show only values above 
2 in order to highlight the spatial extent of the metabolic 
lesion. The choline to creatine index (CCrI) was estimated 
in a similar manner, but with the definition of abnormal vox-
els being based upon those that had been identified during 
the CNI calculation.
To be able to compare across serial exams, levels of cho-
line, creatine, and NAA intensities were normalized by their 
median value in voxels from normal appearing brain (nCho, 
Processing MRI and MRSI data
After each examination, the DICOM images and raw spectral 
data were transferred offline for post-processing. The volu-
metric post-contrast T1 weighted image was used as a refer-
ence and the other images were align d to the same coordinate 
system through rigid body transformations that maximized 
the normalized mutual infor t on [2, 15]. The CE lesion was
manually defined on the post-contrast T1 weighted images. 
Any enhancement that was also present on the pre-contrast 
T1 images was assumed to represent acute blood products 
and was excluded. The T2 lesion was seg nted based on the 
region of hyperintensity on FLAIR images. The resection cav-
ity was excluded from all ROIs. T1 subtraction images [16] 
were generated from the pre- and post-c ntrast T1-weighted 
images and the T1s lesion was identified by thresholding the 
region of hyperintensity with n th T2 region. Norm l appear-
ing brain was identified by brain extraction, followed by 
removal of regions within the T2 lesion ROI.
The spectral data were processed as described previ-
ously [17, 18] to provide levels of cholin , creati e, NAA, 
lactate and lipid. The choline-NAA index (CNI) is a metric 
Fig. 1 Anatomic images, spectra and CNI color overlays from the 
Fup1 scan for a 47 year old female patient with a KPS of 90, sub-total 
resection, a low PFS of 159 days and a low OS of 206 days. The CNI 
maps were thresholded to show only values that were 2 or higher in 
order to highlight the metabolic lesion. The median and maximum CNI 
were 4.8 and 19.9. Note the high lipid peaks in the cavity, which are 
surrounded by areas with increased choline and decreased NAA that 
corresponded to the metabolic lesion. The residual CE volume was 3 cm3
is m nimal and corresponds mainly to a thin rim around the resection. 
The volume the T2 lesion at this time point is 29 cm3. As is s own 
from the FLAIR images and CNI overlays f om the three lower slices, 
the metabolic lesion is relatively large and gives a clear picture of 
regions that are likely to reflect recurrent/residual tumor
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was only 11.2 cm3. This indicates that there were sub-
regions of FLAIR hyperintensity with CNI <2, as well as 
regions of normal appearing brain with elevated CNI. For 
the 19 patients with metabolic imaging data at all 4 scans, 
the changes in mean CNI2 volume from pre-RT to post-RT 
and from pre-RT to Fup1 were significant (from 25.2 to 
16 cm3, p = 0.0017 and 17.2 cm3, p = 0.0145 respectively). 
The differences in spatial extent of the anatomic and meta-
bolic lesions became even more extreme after treatment, 
with the overlap between the CNI2 and T2 lesion volumes 
being 4.6 cm3 at post-RT and 3.8 cm3 t Fup1. As can be 
seen from the lower bar graphs in Fig. 2, the sum(CNI), 
sum(CCrI), sum(nLac) and sum(nLip), which represent 
how abnormal the metabolite levels were within the CNI2 
region from each time point relative to values in normal 
brain showed a similar pattern of changes.
Serial results from individual patients
Figure 3 shows an example of the serial anatomic images 
and overlays of CNI maps from pre-RT, post-RT, Fup1 and 
at two later time points prior to progression for a 47 year 
old patient who had received a sub-total resection, and had 
a KPS of 70, with PFS of 330 days and OS of 706 days. 
The images on the upper panel are from the post-contrast 
T1-weighted sequence and show that the enhancing lesion 
virtually disappears by post-RT (from an overall volume of 
6.7 cm3 at pre-RT to 0.5 cm3 at Fup1) and a small region 
of new enhancement appears in the corpus callosum at the 
11month follow-up scan. The FLAIR images on the bottom 
panel show a large T2 lesion at pre-RT (overall volume of 
55 cm3) with two components, one being brighter and the 
other being less intense. The T2 lesion was smaller at the 
post-RT and Fup1 scan but was beginning to impinge upon 
the corpus callosum at the 8 month scan and then contin-
ued expanding in the 11 month scan. The CNI2 region rep-
resented by the color overlay images in the middle panels 
included only a portion of the T2 lesion. The maximum CNI 
at pre-RT was 20.5 and at Fup1 it was 18.6, suggesting that, 
despite the lack of enhancement, there was substantial resid-
ual tumor. On the 8 month and 11 month scans the CNI2 
lesion increased in size and had clearly crossed the corpus 
callosum, but was still smaller than the overall T2 lesion.
Figure 4 shows a similar time course for a second patient 
who was 38 years old, had a KPS of 90, a biopsy only, simi-
lar PFS of 360 days and a shorter OS of 434 days. The over-
all CE lesion volume at the pre-RT scan was 5.5 cm3 but 
reduced to <1 cm3 on subsequent scans. The T2 lesion had an 
overall volume of 37 cm3 at pre-RT, reducing at the post-RT 
scan and 4 month scans to 25 cm3 and 20 cm3 respectively. 
At the 11 month scan, the T2 lesion volume was similar in 
size on the axial slice shown but had expanded on inferior 
slices. The metabolic lesion had high CNI values at all time 
nCr and nNAA). Signals from lipid and lactate peaks were 
normalized with the median NAA from voxels n normal 
appearing brain (nLac and nLip). Parameters considered for 
analysis were the volume of the CNI2 and the median, max-
imum and summation of voxel values for the CNI, CrI, 
nLac and nLip from within the CNI2 regions at each of the 
four time points.
Statistical analysis
Serial changes in imaging parameters were ev luated usi g 
Wilcoxon signed rank sign tests or paired analysis. Associ-
ation with PFS and OS was as essed using Cox roportional 
hazards analysis, taking into account pa i nt age and extent 
of resection. The cut-off for defining a significant result in 
this exploratory study was a P value of 0.05.
Results
The median PFS for these patients was 404 days with 27 
events and 4 subjects censored. The m dian OS was 603
days with 23 events and 8 subjects c sored. The  were 
16 females and 15 males: medi n age was 52 years with 
a range of 21 to 75, median KPS was 90 with a range of
60–90. There were 9 patients who were designated b sed 
upon clinical criteria as having received a g oss total resec-
tion, 17 who had a sub-total resec ion and 5 who were char-
acterized as having a biopsy.
Changes in anatomic lesion volume
For the 22 patients who had anatomic scans at all 4 time points 
there were overall reductions in the volumes of the anatomic 
lesions with treatment. The m an pre-RT T2 lesion volume 
was 36.2 cm3, which subsequently d cr ased to 28.9 cm3 at 
mid-RT (p > 0.05), to 15.3 cm3 at post-RT (p < 0.0001) and 
to 14.7 cm3 at Fup1 (p = 0.0002). The mean CE lesion vol-
ume decreased from 5.2 cm3 at pre-RT to 3.0 cm3 a  mid-RT 
(p =0.018), 2.1 cm3 at post-RT (p = 0.0002) and 0.7 cm3 at 
Fup1 (p < 0.0001). The mean T1s volume was obtained by 
thresholding the T1 subtraction image and showed similar 
changes to the CE lesion volumes b t was overall arger in 
size at all four time points (mean volumes of 9.4, 5.8, 3.3 
and 1.7 cm3 respectively). These result ar  represented in 
the bar graphs in Fig. 2.
Changes in metabolic paramet rs
At pre-RT, the CNI2 lesion volumes were much l rger than 
the CE and T1s lesions (mean of 25.2 vs. 5.2 and 9.1 cm3 
respectively). Although many of the T2 les on volume  at 
pre-RT were larger than the CNI2 l ions, the mean ov rlap 
1 3
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for PFS (p = 0.029). In contrast, a large number of the meta-
bolic imaging parameters considered in the analysis were 
associated with PFS and OS at the Fup1 (4 month) scan (see 
Table 1). If the population was divided into cohorts with 
survival either shorter or longer than the median value, 
it was observed that there were significant reductions in 
metabolite levels for both cohorts and that these changes 
were observed at both the post-RT and the Fup1 scans. This 
was true when using both the median PFS and median OS 
to define the cut-points.
Discussion
The results of our study highlighted the substantial changes 
in anatomic lesion volumes that are seen in treatments that 
include anti-angiogenic agents such as bevacizumab. The 
RANO criteria for assessing response to therapy in patients 
points (the maximum CNI at pre-RT was 25.6 and at Fup1 
was 22.9). At the initial time points, the region with CNI >2 
covered the majority of the T2 lesion, suggesting that here 
was substantial non-enhancing tumor. While the CNI2 lesion 
changed in shape during the initial 8 months, it was fairly 
stable in size until the 11month scan wh n it b came sub-
stantially larger and extended beyond the T2 lesion. There 
was no evidence of enhancem nt n the pos -Gadolinium 
T1-weighted at this time. Once more, the metabolic data
were helpful in providing confidence that the increase in the 
volume of the T2 lesion corresponded to infiltrative tumor. 
The large increase in the CNI2 lesion volume at progression 
was consistent with the relatively short OS.
Association with survival
The only anatomic imaging parameter that showed an sso-
ciation with outcome was the volume of the CEL at post-RT 
Fig. 2 Changes in mean anatomic, choline, lactate and lipid param-
eters for patients with scans at all four time points (pre-, mid-, post-RT 
and Fup1). The asterisks denote time points at which the change from 
pre-RT in the relevant parameter was statistically significant. The sum 
values re integra s of the various parameters from voxels within the 
region with CNI >2. There were 21 subjects with anatomic data and 19 
subjects with m tabolic data at all 4 time points
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scan. It is presumably a reflection of whether the lesion was 
sensitive and showed an immediate response to this agent.
An alternative approach that has been suggested for 
assessing changes in tumor burden is to use 3-D H-1 MRSI 
to evaluate regions with abnormal metabolism [22–24]. The 
CNI and related metrics such as the ratio of choline to NAA 
have previously been shown to be increased in tumor [20], 
and to detect areas of infiltrative tumor outside of the CE 
lesion [21]. This may be important for targeting radiation 
and other focal therapies, as well as monitoring response to 
treatment [22–29]. Of particular interest is our prior study 
of patients with newly diagnosed GBM being treated with 
radiation and temozolomide [12], which indicated that met-
abolic parameters reduced from pre- to post-RT and that 
values obtained from the post-RT scan were associated with 
overall survival.
The results of the current study indicate that there is only 
partial overlap between the CNI2 and T2 lesions, with there 
with GBM depend upon changes in c oss se tional d am-
eter of the CE lesion, with condary evaluation of the T2 
lesion [8]. This is problematic for treatm nts including anti-
angiogenic agents because the ize of the enhancing por-
tion becomes too small for further evaluation, while the 
T2 lesion may include a mixture of non-enhanc ng t mor 
and non-specific treatment effects. Of interest in the current 
study is that the major reduction in the T2 lesion volume 
occurred between the mid- and p st-RT scan, whereas the 
volumes of the CE and T1 subtraction lesions were signifi-
cantly reduced at the mid-RT scan a d continued decreasing 
for the next two scans. These observations are consistent 
with prior reports of changes in lesion volumes that are
observed following treatment w th nti-angiog ni  agents
and have been attributed to normalizat on o  the vasculature 
in the tumor and associated reduction n edema [2–7]. Of 
interest is that the only anatomic parameter associa ed with 
PFS was the volume of the enhancing l sion at the post-RT 
Fig. 3 Serial post-Gad T1-weighted, FLAIR images and overlaid 
CNI maps for a male patient who was 47 years old, had a PFS of 330 
days and OS of 706 days. The yellow boxes indicating PRESS selected 
volumes are oblique for follow-up scans because the 3D imaging and 
spectr l data were post-processed to register them to the pre-RT exam 
in rder to aid in making visual comparisons
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Fig. 4 Serial post-Gad T1-weighted, FLAIR images and overlaid CNI 
maps for a female patients who was 38 years old, had a PFS = of 360 
days and OS of 434 days. The yellow boxes indicating PRESS selected 
volumes are oblique for follow-up scans because the 3D imaging and 
spectral data were post-processed to register them to the pre-RT exam 
in order to aid in making visual comparisons
 
ParametersProgression free survivalOveral  survival
Pre-RTMid-RTPost-RTFup1 Pre-RTMid-RTPost-RTFup1
Anatomic imaging
Volume (T2)NS NS NS NS NS NS NS NS
Volume (CE) NS NS 0.0299 NS NS NS NS NS
Volume (T1s)NS NS NS NS NS NS NS NS
Metabolic imaging
Volume(CNI2) NS NS NS 0.0046 NS NS NS 0.0080
Sum(CNI) NS NS NS 0.0034 NS NS NS 0.0033
Sum(CCrI) NS NS NS 0.0033 NS NS NS 0.0040
Sum(nLac) NS NS NS 0.0019 NS NS NS 0.0010
Sum(nLip) NS NS NS 0.0001 NS NS NS 0.0034
Metrics with p < 0.05 were considered to be significant but all of the metabolic parameters have much 
smaller P values. The number of subjects with anatomic imaging data at the each of the time points was 
29, 25, 25 and 27, while the number of subjects with metabolic imaging data was 28, 24, 21 and 26. There 
were 4 subjects censored for PFS and 10 subjects censored for OS
Table 1 Association of imag-
ing and metabolic parameters 
with survival based upon Cox 
proportional hazards analysis, 
adjusting for age and extent of 
resection
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bolically abnormal and regions of normal appearing brain 
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the CNI maps that are presented in the figures are helpful in 
relating the metabolic and anatomic data in a visual manner. 
A critical factor to note he e is that although 9/31 patients in 
our study were assessed based on clinical crit ria as having 
a gross total resection, all of the subjects ha  regions with 
metabolic parameters that were consistent with tumor.
Another property of the MRSI ata is that they provide 
measurements of levels of multiple metabolites that can be 
quantified and tracked with time. The reductions in param-
eters reflecting abnormal levels of choline relative to NAA 
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surrogate measures of the eff ctiveness of different treat-
ments. Including consideration of these metabolic param-
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1 cm3, the impressive results th t ave b en obtained in this 
study suggest that it provides complementary information 
to other imaging modalities. Future clinical studi s should 
be designed to include the acquisition of metabolic imaging 
data in order to determine whether these result  hold for  
larger cohort of patients.
Conclusions
This study supports the hypothesis that levels of choline, 
creatine, NAA, lactate and lipid change in response to treat-
ment and that metrics describing these characteristics are 
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treatment effects and for predicting outcome.
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